The real situation of Hengrui

Hengrui Pharma is committed to developing innovative drugs.

Recently, it was reported that it had laid off a large number of employees. However, this is not the case. Hengrui Pharma said that the layoffs were due to the adjustment and optimization of the company's business, mainly to develop innovative drugs to meet clinical needs. For some employees who repeatedly work and fail to meet performance standards, instead of mass layoffs. At the same time, Hengrui Pharma is constantly recruiting new employees to meet the needs of the company's business development.

Its research and development strength is in a leading position in the domestic pharmaceutical industry, and the company has several product lines under research, including small molecular chemicals, biological products and traditional Chinese medicine.

To sum up, the actual situation in Hengrui Pharma is that the company constantly adjusts and optimizes its business to adapt to market changes and competitive environment, rather than laying off employees substantially. At the same time, the company is constantly strengthening the strength of R&D, exploring new markets and businesses, so as to realize the company's sustainable development.

The development course of Hengrui

1, Hengrui Pharma was established in 2000, mainly engaged in the research and development and production of generic drugs.

In 2003, the company began to develop anti-tumor drugs.

3. In 2006, Hengrui Pharma was successfully listed on the Shanghai Stock Exchange.

4. In 2008, the company established Hengrui American branch and began to lay out the international market.

On 20/514, Hengrui Pharma acquired EpitomePharmaceuticals Company of the United States, and obtained the candidate drugs for treating lymphoma.

6.20 15, the company established Hengrui Swiss branch, which further strengthened the cooperation with European pharmaceutical companies.

In 7.20 16, Kangruile monoclonal antibody, a PD- 1 inhibitor developed by Hengrui Pharma for the treatment of gastric cancer, went on the market in China, becoming the first independently developed PD- 1 inhibitor in China.

8.20 18, the company successfully developed the ARB drug candesartan for the treatment of hypertension, which filled the gap in this field in China.

On September 2019, Hengrui Pharma acquired Velcade Company of the United States and obtained the candidate drugs for the treatment of myeloma.

The above contents refer to Baidu Encyclopedia-Hengrui.